Supernus Pharmaceuticals, Inc. (SUPN) financial statements (2021 and earlier)

Company profile

Business Address 9715 KEY WEST AVENUE
ROCKVILLE, MD 20850
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4233473561409062
Cash and cash equivalents2891811921006633
Short-term investments134166164402429
Receivables14187103664226
Inventory, net of allowances, customer advances and progress billings482726161713
Inventory482726161713
Other undisclosed current assets19129735
Total current assets:630473493228151106
Noncurrent Assets
Operating lease, right-of-use asset 21
Property, plant and equipment38174544
Long-term investments and receivables3505924191347555
Long-term investments3505924191347555
Intangible assets, net (including goodwill)442253136161
Goodwill78     
Intangible assets, net (excluding goodwill)364253136161
Deferred costs    2023
Deferred income tax assets 32
Other noncurrent assets4310000
Deferred tax assets, net302142 
Total noncurrent assets:87468848419615883
TOTAL ASSETS:1,5041,160978424310189
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities795052503529
Accounts payable 103784
Accrued liabilities793737272725
Taxes payable 21216  
Debt43    
Business combination, contingent consideration, liability31     
Other liabilities9     
Other undisclosed current liabilities122108109734527
Total current liabilities:2451611611238157
Noncurrent Liabilities
Long-term debt and lease obligation390376329 47
Long-term debt, excluding current maturities362345329 47
Operating lease, liability2930
Liabilities, other than long-term debt1249111145
Deferred income tax liabilities35 
Other liabilities439111144
Business combination, contingent consideration, liability46     
Derivative instruments and hedges, liabilities    01
Other undisclosed noncurrent liabilities 1923232931
Total noncurrent liabilities:514404363343744
Total liabilities:759565525157118101
Stockholders' equity
Stockholders' equity attributable to parent74559545326719288
Common stock000000
Additional paid in capital409388370295276264
Accumulated other comprehensive income (loss)97(3)(1)(0)(0)
Retained earnings (accumulated deficit)32620086(27)(84)(176)
Total stockholders' equity:74559545326719288
TOTAL LIABILITIES AND EQUITY:1,5041,160978424310189

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues520393409302215147
Revenue, net294210144
Cost of revenue(66)(17)(15)(15)(12)(8)
Cost of goods and services sold(52)(17)(15)(15)(12)(8)
Gross profit:455376394287203139
Operating expenses(281)(228)(249)(187)(149)(118)
Operating income:1741491441005421
Nonoperating income (expense)(5)(1)(4)1(4)(6)
Investment income, nonoperating  14321
Other nonoperating income (expense)(5)(1)  (0)0
Interest and debt expense(19)(18)(14)(0)(1)(2)
Income from continuing operations before equity method investments, income taxes:1491291261005012
Other undisclosed income from continuing operations before income taxes191814012
Income from continuing operations before income taxes:1691471401015015
Income tax expense (benefit)(42)(34)(29)(43)41(1)
Net income available to common stockholders, basic:127113111579114
Interest on convertible debt   011
Dilutive securities, effect on basic earnings per share   0(0)0
Net income available to common stockholders, diluted:127113111579116

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net income:127113111579114
Comprehensive income:127113111579114
Other undisclosed comprehensive income (loss), net of tax, attributable to parent211(2)(1)0(0)
Comprehensive income, net of tax, attributable to parent:129124109579214

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: